Back to news

Lexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026

Globe Newswire•15/11/2026•07:00 ET
1

Key Highlights

  • ➤Lexeo (LXEO) will report Q3 2026 results November 16, 2026
  • ➤LX2020 business update will cover the ongoing HEROIC-PKP2 Phase I/II trial
  • ➤LX2020 targets PKP2 arrhythmogenic cardiomyopathy using AAV-based gene therapy
  • ➤PKP2 mutations cause approximately 50% of ACM cases, affecting approximately 60,000 Americans

NEW YORK, Nov. 15, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced it will report third quarter 2026 financial results and provide a business update on the ongoing HEROIC-PKP2 Phase I/II clinical trial of LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM) on Monday, November 16, 2026.

A webcast will be held at 8:00 AM ET on November 16, 2026. Analysts and investors can access the live event through the Events & Presentations page in the Investors section of Lexeo’s website. A replay will be available following the call.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in